跳至主要内容
临床试验/NCT04285320
NCT04285320Unknown4 期

Intravesical Antibiotic Instillations Versus Oral Suppression for the Treatment of Recurrent Urinary Tract Infections in Post-menopausal Women

Atlantic Health System0 个研究点目标入组 100 人开始时间: 2021年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
100
主要终点
The percentage of participants with urinary tract infections following treatment course

研究概览

简要总结

This is a research study that aims to determine if antibiotic bladder instillations (placing an antibiotic directly into the bladder) over several sessions at the office is a good option to prevent recurrent urinary tract infections, in comparison with oral suppression therapy (taking daily antibiotics in the form of pills by mouth). Oral antibiotic suppression therapy is currently the most common treatment route for recurrent urinary tract infections in post-menopausal women. The bladder antibiotic instillation may overcome the disadvantages of oral suppression therapy such as antibiotic resistance, certain side effects, and recurrence of infections after finishing the treatment course.

详细描述

In this study, the investigators aim to determine the effectiveness of intra-vesical antibiotic instillations for the prophylactic treatment of recurrent urinary tract infections in menopausal women in comparison with oral suppressive therapy. This is a parallel un-blinded randomized-controlled trial. the investigators will randomize post-menopausal women with recurrent urinary tract infections to either receive 6-8 intra-vesical antibiotic instillations at the office or to receive 3 months of oral antibiotic suppressive therapy.

In the bladder instillation arm, based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:

  • Amikacin-30 mg in 60 ml of sterile water
  • Gentamycin-80mg in 60ml sterile water
  • Tobramycin-80 mg in 100 ml of sterile water

In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:

  • Trimethoprim daily (100 mg)
  • Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)
  • Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)
  • Nitrofurantoin monohydrate/macrocrystals daily (50 mg)
  • Nitrofurantoin monohydrate/macrocrystals daily (100 mg)
  • Cephalexin daily (125 mg)
  • Cephalexin daily (250 mg)
  • Fosfomycin every 10 days (3 grams) All medications used in this study are approved by the FDA to treat urinary tract infections.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • Post-menopausal women with recurrent urinary tract infections (2 infections in a 6-month period or at least 3 infections in a 1-year period)
  • Receiving estrogen vaginal therapy for 1 month prior to enrollment
  • Able to come in to the office twice weekly for 3-4 weeks
  • English speaking
  • No allergy to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy.
  • No uro-pathogen resistance to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy.

排除标准

  • Allergy to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin)
  • Recent Urine culture with pathogens resistant to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin)
  • Renal failure (Creatinine clearance <30ml/min)
  • History of urinary retention
  • History of genitourinary structural abnormalities

研究组 & 干预措施

Intravesical antibiotic instillation

Active Comparator

干预措施: Intravesical antibiotic instillation (Drug)

Oral antibiotic suppressive therapy

Active Comparator

干预措施: Antibiotic oral suppressive therapy (Drug)

结局指标

主要结局

The percentage of participants with urinary tract infections following treatment course

时间窗: Assessed starting immediately after the treatment is completed for a total of 3 months.

To compare the percentage of women developing urinary tract infections during the 3 months following treatment between the two groups.

次要结局

  • The rate of antibiotic resistance of pathogens in participants developing urinary tract infections after completing the treatment course.(Assessed starting immediately after the treatment is completed for a total of 3 months)
  • the percentage of patients developing side effects of the 2 treatments(From the date of randomization until the date of first documented side effect assessed up to 3 months after the treatment is completed in each arm)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

charbel salamon

Director, Urogynecology Division & Fellowship

Atlantic Health System

相似试验